UNSPSC 51281801: Idarubicin

This classification denotes an anthracycline antibiotic with the molecular formula C26H27NO9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZRP63D75JW, chemically known as 5,12-naphthacenedione, 9-acetyl-7-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7s-cis)- but generally known as idarubicin, which bears US NIH Compound Identifier 42890. European Medicines Agency schedules Idarubicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08111MIG.

UNSPSC 51281801 Idarubicin is a Commodity code that encompasses pharmaceutical products and related medical supplies procured by state and local governments, though recent solicitation activity under this specific code shows little direct alignment with idarubicin itself. Instead, state and local buyers are actively soliciting a broader range of pharmaceutical products, over-the-counter medications, emergency medical supplies, and naloxone through cooperative purchasing vehicles and direct competitive bids. The issuing bodies span state health and human services agencies, county health departments, municipal fire departments, and multistate cooperative purchasing alliances. Work solicited includes generic pharmaceutical sourcing through wholesaler networks, emergency medical and first-aid supplies for rescue operations, naloxone procurement for community health initiatives, and direct-to-manufacturer prescription program development.

Recent activity appears concentrated in Florida, Minnesota, and Texas, with multistate cooperative purchasing playing a significant role. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, requiring vendors to supply through authorized wholesalers and maintain cGMP and DSCSA compliance. Seminole County, Florida posted an IFB on June 30, 2026 (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The City of Tampa's Purchasing Department solicited sealed bids (26P00145, due March 13, 2026) for 169 line items of medical and first-aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5 percent bid discount set-aside for certified Small Local Business Enterprises. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026 to gather vendor capabilities regarding direct-to-manufacturer pharmaceutical prescriptions, signaling early-stage state procurement strategy development in this space.